Table 1 Patients included in this study
No. | Age | Gender | Sampling | Clinical T-staging | pT stage | NAC | NAC response | LN | Tumor | Year |
|---|---|---|---|---|---|---|---|---|---|---|
1 | 73 | M | T | cTaG2 | – | – | – | – | Tumour | 2017 |
2 | 81 | F | T, C | cT3 | pT3 | – | – | 4 | Tumour | 2017 |
3 | 60 | F | C | cT2 | pTa-pTis | NAC | PR | 2 | – | 2017 |
4 | 70 | M | T | cTaG3 | – | – | – | – | Tumour | 2017 |
5 | 82 | M | T | cT3 | – | – | – | – | Tumour | 2017 |
6 | 73 | M | C | cT2 | pTa-pTis | – | – | 3 | Tumour | 2017 |
7 | 74 | M | C | cT2 | pT3 | NAC | prog. | 3 | – | 2017 |
8 | 62 | M | C | cT2 | pT0 | NAC | CR | 5 | – | 2017 |
9 | 73 | M | C | cT2 | pT3 | NAC | prog. | 4 | – | 2017 |
10 | 57 | F | C | cT2 | pT0 | NAC | CR | 9 | Tumour | 2017 |
11 | 70 | M | C | cT2 | pT1 | NAC | PR | 2 | – | 2017 |
12 | 68 | M | T | cT1 | – | – | – | – | Tumour | 2017 |
13 | 68 | M | C | cT2 | pT0 | NAC | CR | 6 | – | 2017 |
14 | 73 | M | T | cT2 | – | – | – | – | Tumour | 2017 |
15 | 61 | F | T | cTaG2 | – | – | – | – | Tumour | 2017 |
16 | 75 | M | C | cT2 | pT0 | NAC | CR | 1 | – | 2017 |
17 | 70 | F | T | cTaG2 | – | – | – | – | Tumour | 2017 |
18 | 73 | F | T, post Ch | cT3 | – | NAC | – | – | Tumour | 2017 |
19 | 64 | F | T, C | cT2 | pT2 | NAC | NR | 4 | Tumour | 2017 |
20 | 71 | M | C | cT2 | pT2 | NAC | NR | 7 | – | 2017 |
21 | 77 | M | T | cT1 | – | – | – | – | Tumour | 2017 |
22 | 72 | M | T, post Ch | cT2 | – | NAC | – | – | Tumour | 2017 |
23 | 61 | M | T | cT1 + CIS | – | – | – | – | Tumour | 2017 |
24 | 68 | M | C | cT2 | pT0 | NAC | CR | 2 | – | 2017 |
25 | 79 | F | T | cT2 | – | – | – | – | Tumour | 2017 |
26 | 74 | M | T | cTaG2 | – | – | – | – | Tumour | 2017 |
27 | 67 | M | C | cT2 | pTa-pTis | NAC | PR | 4 | – | 2017 |
28 | 67 | F | T | cT2 | – | NAC | – | – | Tumour | 2017 |
29 | 79 | M | T | cT1 | – | – | – | – | Tumour | 2017 |
30 | 84 | F | T | Benign | – | – | – | Tumour | 2017 | |
31 | 71 | M | C | cT2 | pT0 | NAC | CR | 5 | – | 2017 |
32 | 75 | M | T | cTaG2 | – | – | – | – | Tumour | 2017 |
33 | 69 | F | T, post Ch | cT4a | – | – | – | – | – | 2017 |
34 | 50 | M | T, C post Ch | cT2 | pT0 | NAC | CR | 4 | – | 2015 |
35 | 56 | M | C | cT2 | pT0 | NAC | CR | 3 | – | 2015 |
36 | 79 | M | C | cT3 | pT3 | NAC | NR | 4 | – | 2015 |
37 | 59 | F | T | cT3 | – | – | – | – | Tumour | 2017 |
38 | 80 | M | C | cT2 | pT0 | – | – | 4 | – | 2017 |
39 | 60 | M | T, C post Ch | cT3 | – | NAC | prog. | – | – | 2014 |
40 | 66 | M | T, C post Ch | cT3 | – | NAC | CR | – | – | 2017 |